SCHEDULE 13G 0001873032 XXXXXXXX LIVE Common Shares, par value $1.00 per share 03/31/2025 0001877184 Kestra Medical Technologies, Ltd. G52441105 3933 Lake Washington Blvd NE Suite 200 Kirkland WA 98003 Rule 13d-1(d) Endeavour Medtech Growth II LP b Y7 0 2646899 0 989574 2646899 N 5.2 PN The percent of class is calculated based upon 51,348,656 Common Shares outstanding as of April 17, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on April 17, 2025. Endeavour Medtech Growth II Parallel LP b Y7 0 2646899 0 989574 2646899 N 5.2 PN The percent of class is calculated based upon 51,348,656 Common Shares outstanding as of April 17, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on April 17, 2025. Endeavour Medtech II GP Limited b Y7 0 2646899 0 989574 2646899 N 5.2 CO The percent of class is calculated based upon 51,348,656 Common Shares outstanding as of April 17, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on April 17, 2025. Kestra Medical Technologies, Ltd. 3933 Lake Washington BLVD NE, Suite 200, Kirkland, WA 98003 This Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"): (i) Endeavour Medtech Growth II LP (ii) Endeavour Medtech Growth II Parallel LP (iii) Endeavour Medtech II GP Limited The address and principal business address of each of the Reporting Persons is P.O. Box 656, East Wing Trafalgar Court, Les Banques, St. Peter Port, Guernsey GY1 3PP. Endeavour Medtech Growth II LP is a Guernsey limited partnership. Endeavour Medtech Growth II Parallel LP is a Guernsey limited partnership. Endeavour Medtech II GP Limited is a Guernsey company limited by shares. Y 972,077 Common Shares are held of record by Endeavour Medtech Growth II LP and 1,628,023 Common Shares are indirectly held by Endeavour Medtech Growth II LP through West Affum Holdings, L.P., which Endeavour Medtech Growth II LP is entitled to receive, calculated for the purposes of this Statement based on the liquidation value of West Affum Holdings, L.P. immediately following the initial public offering of the Issuer, pursuant to an agreement between West Afum Holdings, L.P. and its partners to distribute Common Shares of the Issuer held by West Affum Holdings, L.P. to its partners approximately nine months after the consummation of the Issuer's initial public offering (the "Post-IPO Distribution"). 17,497 Common Shares are held of record by Endeavour Medtech Growth II Parallel LP and 29,302 Common Shares are indirectly held by Endeavour Medtech Growth II Parallel LP through West Affum Holdings, L.P., which Endeavour Medtech Growth II Parallel LP is entitled to receive in connection with the Post-IPO Distribution, calculated for the purposes of this Statement based on the liquidation value of West Affum Holdings, L.P. immediately following the initial public offering of the Issuer. The actual number of Common Shares that Endeavour Medtech Growth II LP and Endeavour Medtech Growth II Parallel LP will be entitled to receive pursuant to the Post-IPO Distribution will be determined in reference to the liquidation value of West Affum Holdings, L.P. at the time of the Post-IPO Distribution. Endeavour Medtech II GP Limited is the general partner of Endeavour Medtech Growth II LP and Endeavour Medtech Growth II Parallel LP. West Affum Holdings, L.P. holds Common Shares for the benefit of holders of its common units, including Endeavour Medtech Growth II LP and Endeavour Medtech Growth II Parallel LP, until the time such Common Shares are distributed to the holders of its common units pursuant to the Post-IPO Distribution. The Reporting Persons disclaim beneficial ownership of the Common Shares held by West Affum Holdings, L.P. on behalf of third-party holders of common units of West Affum Holdings, L.P. The Reporting Persons have the right to direct the votes of, but do not have dispositive power over, the Common Shares indirectly held by the Reporting Persons through West Affum Holdings, L.P. See responses to Item 11 on each cover page. See responses to Item 5 on each cover page. See responses to Item 6 on each cover page. See responses to Item 7 on each cover page. See responses to Item 8 on each cover page. Y Y Y N Due to the relationships between them, the Reporting Persons hereunder may be deemed to constitute a "group" with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934. Y Y Endeavour Medtech Growth II LP /s/ Nick Barton 05/15/2025 Endeavour Medtech Growth II Parallel LP /s/ Nick Barton 05/15/2025 Endeavour Medtech II GP Limited /s/ Nick Barton 05/15/2025 Exhibit A Joint Filing Agreement, dated as of May 15, 2025